DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous PolyposisUnderscores unmet need for a ...

Researchers from the University College Cork have described the neuroprotective effect of TMP-269, a class-IIa-specific histone deacetylase (HDAC) inhibitor in preclinical models of PD. Pan-inhibitors ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Short-chain fatty acids (SCFAs) like propionate and butyrate are critical byproducts of dietary fiber digestion. These molecules do more than fuel the body—they directly influence gene expression and ...

Biodexa Strengthens Management TeamAppointment of Dr Gary A. Shangold as Chief Medical OfficerBiodexa Pharmaceuticals PLC ...

GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a specialty pharmaceutical company with a current market capitalization of $3.08 million, has reached a milestone in its Phase ...

Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan International Master Program in ...

Histone deacetylase inhibitor. Givinostat (Duvyzat) is the first non-steroid drug approved to treat people with all genetic variations of DMD. It delays the disease's progression by targeting an ...

Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda 151 401, India ...